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Abstract
Background: In clinical practice, the common strategy for immunotherapy of
nasopharyngeal carcinoma (NPC) is to infuse cytotoxic T-lymphocyte (CTL) lines
several times by intravenous injection, but it is difficult by laboratory research to
investigate the relationship between treatment time-point, the amount of CTL added
and the therapeutic effect. The objective of this study is to establish a mathematical
model to study the therapeutic effect of different treatment time-points and
amounts of CTL, and to predict the change in therapeutic effect when the
percentage of EBV LMP2-specific CTL is increased from 10% to 20%.
Results: The concentration of epidermal growth factor receptor (EGFR) in the tumor
cell cytomembranes increases after CTL is added. Concurrently, there is a marked
downward trend of the phosphorylated transforming growth factor-a (TGFa)-EGFR
complex in the tumor cell cytomembranes, which indicates restriction of tumor
growth after CTL immunotherapy. The relationships among the time of addition of
CTL, the amount of CTL added, different CTL specificities for LMP2 and the
increment rate k of the total number of tumor cells were evaluated.
Conclusions: The simulation results quantify the relationships among treatment
time-points, amount of CTL added, and the corresponding therapeutic effect of
immunotherapy for NPC.
Background
Epstein-Barr virus is present in virtually all poorly-differentiated and undifferentiated
nasopharyngeal carcinomas (NPC) and the viral antigens expressed by the tumor pro-
vide potential targets for immunotherapy [1]. NPCs only express a restricted set of less
immunogenic viral antigens (latency type II), namely EBNA-1, LMP-1 and LMP-2. The
most likely target antigen for a CD8+ cytotox i cT - l y m p h o c y t e( C T L ) - b a s e dt h e r a p yi s
LMP-2.
A pilot study using adoptive T cell therapy to treat NPC was reported in 2001 [2].
Autologous EBV-transformed B-lymphoblastoid cell line (LCL)-reactivated T cells were
generated in vitro and used to treat four advanced cases of NPC. The use of autolo-
gous EBV-specific CTL for NPC has since been evaluated in two clinical trials [3,4].
Both studies demonstrated that autologous EBV-specific CTL is safe, induces LMP-2-
specific immune responses, and is associated with an objective response and control of
disease in advanced NPC. However, the EBV-specific CTL lines in these studies were
generated by stimulation with EBV-LCL, which favored the outgrowth of CTL
Shengjun et al. Theoretical Biology and Medical Modelling 2012, 9:6
http://www.tbiomed.com/content/9/1/6
© 2012 Shengjun et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.responses to the immunodominant EBNA-3 proteins rather than the subdominant EBV
proteins LMP-1 and LMP-2 expressed in NPC. The anti-tumor response could be
further enhanced by strategies that increase the specificities of CTL lines for the EBV
latency II antigens expressed in NPC [1].
How can the success rate of immunotherapy for NPC be increased? Straathof et al.
[ 4 ]p o i n t e do u tt h a tt h eC T L sb e i n gt r a n s f e rred may undergo only limited expansion
in vivo, so strategies aimed at increasing the number of LMP1- and LMP2-specific T
cells in the infusion product may be of value. Fewer than 10% of cells in the CTL lines
mentioned above are LMP2-specific.
The common strategy is to infuse CTL lines several times by intravenous injection in
clinical practice, but it is difficult to investigate the relationships among treatment
time-point, amount of CTL added and therapeutic effect by laboratory research. The
objective of this work is to establish a mathematical model to study the therapeutic
effect of different treatment time-points and amounts of CTL, and to predict the
change in therapeutic effect when the percentage of EBV LMP2-specific CTL is
increased from 10% to 20%.
Methods
The simulation toolkit used in this study is REPAST (Recursive Porous Agent Simula-
tion Toolkit), which originated from the University of Chicago. Its original purpose
was to build a manageable and flexible agent-based modeling (ABM) platform for
social simulation [5]. The current Repast platform has been developed to Repast
Simphony from Repast 3, in which the applications have been extended to natural
science, especially biomedicine [6-8].
The ABM used in this study consists of two models. One is the ABM of tumor
growth built by Athale et al. [9]. The other is Basic Immune Simulator (BIS), which
is an agent-based model created to study the interactions between the cells of the
innate and adaptive immune systems [10], and therefore to simulate the human
immune system. These two models are both built on the platform of Repast 3. In
order to collect data and create diagrams expediently, we input the two models into
Repast Simphony. Some necessary modifications were made to accommodate the
objective of the study.
The computer used in the simulation has an AMD athlon 64 bit dual-core processor
with main frequency of 2.20 GHz and 2 GB RAM memory. It takes about 840 seconds
to complete one simulation.
Model of tumor growth
Our simulation made some appropriate modifications to the ABM of tumor growth
built by Athale et al. [9]. A problem in the algorithm for nutrient diffusion was
resolved. The experimental study by Thornburg et al. [11] indicated that the expressed
EBV protein up-regulates EGFR expression in NPC by 12 fold, and this finding was
incorporated in our simulation model.
The ABM is a multi-scale model that can be studied at different levels - molecular,
microscopic (cell) and macroscopic (tissue). A cell in the model is divided into four
layers: extracellular, membrane, cytoplasm and nucleus. The interactions of different
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tion takes the following generic form:
dXi
dt
= α · Xi − β · Xi
where Xi is the mass of the i
th molecule, a is the rate of synthesis or increase and b
is the rate of degradation or removal of a molecular species. There is an equation for
each molecule. Detailed equations and their parameters can be found in reference [9].
The change of each molecule in every agent (i.e. cell) is calculated at each iteration
step of the simulation. Cells are assigned to be in one of three states, namely migra-
tion, proliferation or quiescence, according to the calculation. Migration means moving
to neighboring grids. Whether or not a cell is in the migration state will be checked
first, and if it is not, the algorithm will evaluate whether it is in the proliferation or
quiescence state. The procedure is as follows:





, Mn is the change in amplitude of PLCg in
the n
th cell before and after an interation. PLCg is active (phosphorylated, Ca-bound)
phospholipase C-g.
② if Mn >sPLC, the cell’s next state will be assigned as migration. The algorithm will
judge further to which neighboring grids it moves.
③ calculating Pprolif[(LR)] = (LR) − σEGFR
where (LR) is the concentration of ligand-bound phosphorylated TGFa-EGFR com-
plex in a cell, sEGFR is the threshold, and Pprolif indicates capacity for proliferation.
This function is derived from experimental observations regarding cell proliferation in
relation to an EGF-receptor threshold [12] and a model that relates receptor occu-
pancy to percentage maximal
proliferation [13]. Specifically, these publications reported experimentally measured
values of cell proliferation in response to EGFR occupancy for some human and rodent
cell lines, and it was demonstrated that sEGFR could reach 25% of the total receptor
concentration [9].
If Mn < sPLC and Pprolif > 0, the cell will proliferate.
If Mn < sPLC and Pprolif < 0, the cell will be quiescent.
Conditions: the virtual environment consists of S = R
2 grids. R is the length of the
lattice side and here R = 200. Each grid can be empty or be occupied by one cell.
There are 100 tumor cells at the center of the grids when the model is initialized.
There is a blood vessel, which is the initial location of the nutrient source from which
glucose diffuses, vertical to the lattice at the center of the SE quadrant. The dynamic
changes of concentrations of four molecules in/out of the tumor cells are recorded in
the simulation. They are: EGFR in cytoplasm (marked as EGFR_i in figure), EGFR in
membrane (EGFR_s), phosphorylated TGFa-EGFR complex in membrane (phos_-
TGFaEGFR_s), and extracellular TGFa (TGFa_ex). For each molecule, the calculation
is carried out for cells inside the tumor tissue and on the tumor tissue surface. It is
mainly in the quiescence state for the former and the proliferation/migration state for
the latter.
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BIS is an agent-based model for studying the interactions between cells of the innate
and adaptive immune systems [10]. The BIS was created with three “zones” of activity
to represent the separate locations in the body where interactions between cells take
place during the course of an immune response. Zone 1 is the site where a tissue initi-
ally challenges the pathogen. Zone 2 is an abstract representation of a lymph node or
the spleen, where lymphocytes reside and proliferate. Zone 3 is an abstract representa-
tion of the lymphatic and blood circulations - the conduits for the cells to travel in the
immune system. Zone 3 was created to contain the agents that represent cells that
must travel for indefinite (unknown) periods of time before arriving at their final desti-
nation, the site of pathological challenge (Zone 1). Thus, Zone 3 can be considered as
the “rest of the body” and circulation apart from the areas of actual infection (Zone 1)
and the areas of immune cell proliferation (Zone 2). The agents representing lympho-
cytes that have proliferated in Zone 2 and the granulocytes are the agent types found
in Zone 3. The portal agents (Portals) in Zone 3 represent spatially discrete blood and
lymphatic vessels controlling the access of the agents to Zone 1. They also transmit
signals produced in Zones 1 and 2 to attract agents to migrate. The Portals also parti-
cipate in the transportation of some signals to Zone 1. Portals are the means of trans-
ferring agents and signals from one zone to another. They are randomly placed in
Zones 2 and 3. The variation and uncertainty in the time spent by immune cells in the
areas represented by Zone 3 is one of the sources of randomness in the BIS.
The agents in BIS include: the dendritic cell agent (DC), the macrophage agent
(MF), the natural killer agent (NK) of the innate immune system, the B cell agent (B),
the T cell agent (T), and the cytotoxic lymphocyte T cell agent (CTL) of the adaptive
immune system. The parenchymal cell agent (PC) in Zone 1 is replaced by the tumor
cell agent (TumorAgent).
On the one hand, TumorAgents carry out proliferation, migration or quiescence
according to the rules in model of tumor growth. On the other hand, they carry out
the rules of PC in BIS. PCs infected by viruses have three possible outcomes:
① to be killed by NKs, pro-inflammatory T cell agents (T1s) or CTLs and undergo
apoptosis;
② to be bound by antibodies (Ab) making them a target for recognition by pro-
inflammatory macrophage agents (MF1s);
③to be lysed by complement products (C’) if antibody 1 (Ab1) is present.
An attribute named isSpectToLMP2 is added to the CTL agent, which indicates
whether the CTL is LMP2-specific. When a CTL makes contact with a TumorAgent,
the attribute effectiveContacts_CTL of the latter will increase by foldCTLSpectLMP2;
otherwise, it will increase by 1.
The basic idea of combining the tumor growth model and BIS in this paper is:
TumorAgent grows in Zone 1. Concurrently, it is also infected with viruses that initiate
defense by the immune system.
CTL immunotherapy is realized by infusing the CTL lines cultured in the laboratory
into patients. In the simulation, this process is realized by adding CTLs into Zone 3.
There are 100 Portals leading to Zone 1 in Zone 3. CTLs move randomly in Zone 3,
and they enter Zone 1 when they meet a functional Portal.
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tion into Zone 3. The number of CTLs added is fixed at 1800. The first round is at
tick = 200, and the second is at tick = 200 ~ 254 with an interval of six ticks. This
ensures that there are nine treatments with 10% of CTLs specific for LMP2. Ten simu-
lations were carried out for each treatment.
In the second group of simulations, the time of CTL addition is fixed at tick = 200
and 242. The number of CTLs added is from 1000 to 2600 with an interval of 200.
Ten simulations were carried out for each treatment.
The above simulation was repeated for 20% of CTL specific for LMP2.
The total numbers of tumor agents at tick = 200 and 350 were recorded for each
simulation. The increment rate, k, obtained from the latter divided by the former, was
also recorded; it reflects the therapeutic effect.
Results
The effect on EGFR of adding CTL agent
The amount of CTL added was fixed at 1800. The two rounds of adding CTL were
tick1 = 200 and tick2 = 242. Ten simulations were carried out. The average values and
standard deviations of the EGFR concentration (EGFR_s) and the phosphorylated
TGFa-EGFR complex concentration (phos_TGFaEGFR_s) in the tumor cell cytomem-
brane were calculated. The total number of tumor agents decreases after CTL is
added. Corresponding to this, there is a rise in EGFR_s (Figure 1). Synchronously,
there is a marked downward trend in phos_TGFaEGFR_s (Figure 2).
Influence on therapeutic effect of the time-point of CTL addition and the percentage of
LMP2-specific CTL
The amount of CTL added was fixed at 1800. The second round of CTL addition was
from tick2 = 206 to 254 with an interval of six ticks. Ten simulations were carried out
and the average value and standard deviation of increment rate, k, of tumor agents was
calculated for each treatment. As shown in Table 1, the first row is for 10% of LMP2-
Figure 1 The effect of adding CTL agent on EGFR_s.
Shengjun et al. Theoretical Biology and Medical Modelling 2012, 9:6
http://www.tbiomed.com/content/9/1/6
Page 5 of 12specific CTL, and the second row is for 20% of LMP2-specific CTL. Figure 3 shows the
data in Table 1 as a line chart.
Influence on the therapeutic effect of the amount of CTL added and the percentage of
LMP2-specific CTL
The time of adding CTL was fixed at tick = 200 and 242. The amount of CTL added
was from 1000 to 2600 with an interval of 200. Ten simulations were carried out, and
the average and standard deviation of the increment rate k of tumor agents were calcu-
lated for each treatment. As shown in Table 2, the first row is for 10% LMP2-specific
CTL, and the second row is for 20% LMP2-specific CTL. Figure 4 shows the data in
Table 2 as a line chart.
Validation of the model
① Without addition of CTL, the total number of tumor agents shows exponential
growth. As demonstrated in Figure 5, the blue curve gives the total number of tumor
agents; the yellow, red and green curves are the numbers of agents in the quiescence,
migration, and proliferation states, respectively. Figure 6 gives the overall scenario of
tumor agents when the simulation is completed. The green, blue and red dots are
agents in the quiescence, migration, and proliferation states, respectively. The yellow
shades are nutrient content, and the different shades of yellow denote different
Figure 2 The effect of adding CTL agent on phos_TGFaEGFR_s.
Table 1 The relationships among the time-points of CTL addition, the percentage of
LMP2-specific CTL and the increment rate k of tumor agents (¯ x ± s)
percentage of specific CTL n Tick2
206 212 218 224 230 236 242 248 254
10% 10 ¯ x 0.943 1.006 1.014 1.116 1.205 1.107 1.009 1.006 1.124
S 0.094 0.108 0.092 0.116 0.176 0.125 0.073 0.123 0.098
20% 10 ¯ x 0.881 0.924 0.851 0.830 0.861 0.806 0.749 0.832 0.856
S 0.142 0.095 0.094 0.083 0.117 0.077 0.186 0.139 0.162
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nutrient.
② To add CTLs, appropriate parameters need to be chosen. There is no significant
change in the total number of tumor agents from time-point tick = 200 to tick = 350
(Figure 7), which corresponds to controlled tumor growth in clinical treatment. The
simulation result with CTL added is shown in Figure 8. Major parameters used are
listed in Table 3.
Figure 3 The specificity of CTL for LMP2: The relationship between the time points of CTL addition
and the therapeutic effect (¯ x ± s)
Table 2 The relationships among the amount of CTL added, the percentage of LMP2-
specific CTL and the increment rate k of tumor agents (¯ x ± s)
percentage of specific CTL n CTL amount
1000 1200 1400 1600 1800 2000 2200 2400 2600
10% 10 ¯ x 1.640 1.493 1.402 1.260 0.956 0.876 0.887 0.755 0.673
S 0.131 0.089 0.125 0.112 0.068 0.130 0.119 0.096 0.061
20% 10 ¯ x 1.347 1.284 1.171 1.008 0.770 0.744 0.691 0.709 0.519
S 0.111 0.123 0.085 0.066 0.123 0.055 0.062 0.074 0.049
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The signal transduction network of the EGFR plays an important role in organ devel-
opment, epithelization, regulation of cell growth, tumorigenesis and vascularization.
Mutation, overexpression, structural rearrangement or loss of normal regulative func-
tion of EGFR lead to abnormal cell growth and differentiation [14]. Wang et al. [15]
reported that the positive rate for EGFR was 70.9% in NPC tissue. EGFR expression
Figure 4 The specificity of CTL for LMP2: The relationship between amount of CTL added and the
therapeutic effect (¯ x ± s)
Figure 5 The increase of tumor agent without CTL addition. The blue curve gives the total number of
tumor agents. The yellow, red and green curves are the numbers of agents in the quiescence, migration
and proliferation states, respectively
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agents in the quiescence, migration, and proliferation states, respectively. The yellow shades are nutrient
content, and the different shades of yellow denote different concentrations of nutrient
Figure 7 The increase of tumor agent with CTL addition.T h eb l u ec u r v eg i v e st h et o t a ln u m b e ro f
tumor agents. The yellow, red and green curves are the numbers of agents in the quiescence, migration
and proliferation states, respectively
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(TTP). Yuan et al. [16] found that phosphorylated EGFR (pEGFR) was related to
metastasis-free survival of NPC patients. The 5-year metastasis-free survival rate was
significantly lower in patients with high pEGFR expression than in those with low
pEGFR expression. Magkou et al. [17] found that pEGFR expression is related to
angiogenesis and invasiveness and that the EGFR/pEGFR phenotype is associated with
poor patient survival in invasive breast cancer. We found in the simulation that when
CTL is added, the EGFR concentration in the tumor cell cytomembranes (EGFR_s)
Figure 8 The simulation result with CTL addition. The green, blue and red dots represent tumor agents
in the quiescence, migration, and proliferation states, respectively. The yellow shades are nutrient content,
and the different shades of yellow denote different concentrations of nutrient
Table 3 Major parameters in the simulation
Parameter Annotation value setting
a1intAddCTLTick The time at which the initial addition of CTL is made 200 ticks
a1intAddNumCTL Number of CTL added for the first time 1800 ticks
a2intAddCTLTick The time at which the second addition of CTL is
made
206~254, the interval is 6 ticks
a2intAddNumCTL Number of CTL added for the second time 1000~2600, the interval is 200
ticks
intSpectCTLPercent1 The percentage of CTL specific for LMP2 10% or 20%
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lated TGFa-EGFR complex (phos_TGFaEGFR_s, i.e. pEGFR) in those cytomembranes
(Figure 2). This shows that tumor growth is suppressed and the activity of EGFR
declines during CTL immunotherapy, which is consistent with the finding of Yuan et
al. EGFR_s and phos_TGFaEGFR_s transform reciprocally, so the decline of the latter
is followed by the rise of the former.
These simulations provide insights and clues for further clinical experimental
research.
(1) The relationship between the CTL addition time-point and the therapeutic effect
(Figure 3): According to the line chart for 10% LMP2-specific CTL, the increment rate
k climbs from the minimum to the maximal value and then falls and reaches the low-
est point at tick2 = 242 or 248. It begins to increase again at tick2 = 254. However,
according to the line chart for 20% LMP2-specific CTL, k is lower than in the former
case in general but the trend is similar, i.e., it reaches the upper point at tick2 = 230
and the lower point at tick2 = 242. This implies that a better therapeutic effect can be
achieved here. According to the two graphs, better therapeutic effects can be achieved
in both cases at tick2 = 242. One simulation time tick stands for the duration of one
tumor cell proliferation event. This implies that a better therapeutic effect can be
achieved when the CTL is added at 42 times the duration of one tumor cell prolifera-
tion step for both 10% or 20% LMP2-specific CTL, while other conditions are
unaltered.
(2) The relationship between the amount of CTL added and the therapeutic effect
(Figure 4): When the amount of CTL added is increased, the downward trend of k is
similar for both 10% and 20% of LMP2-specific CTL. When the amount of CTL added
increases from 1000 to 1800, k declines by 42.6% more quickly than usual. When the
amount increases from 1800 to 2600, k declines by 30.9% relatively slowly. This sug-
gests that increasing the amount of CTL added can improve the therapeutic effect, but
the degree of improvement achieved with the same addition of CTL declines markedly
after the amount added has increased to a certain level.
In this work, the simulation was conducted in silico. Although the pEGFR result is
consistent with the finding of Yuan et al., the predicted relationship between treatment
time-points, amount of CTL added, and the corresponding immunotherapeutic effect
on NPC is rather difficult to validate in vivo. We expect interested researchers to carry
out related laboratory validation studies. The agent-based quantitative simulation
model built for CTL immunotherapy is an open model. The results from related
laboratory studies in the future can gradually improve the model to attain more abun-
dant, accurate and reliable quantitative simulation results to enhance the effect of
immunotherapy for NPC in the clinic.
Fewer agents are used in this model than occur in vivo, both the tumor agents and
the immune cells in BIS. The maximum number of tumor agents is 3000, which is still
far less than in reality. Moreover, our simulation was carried out on a 2-dimensional
model, and 3-dimensional simulation needs to be conducted in further studies. In two
dimensions, the agents live in lattices located in one plane. This means that only one
layer of agents is studied. Three-dimensional simulation is for multilayer agents and is
more appropriate for modeling biological tissues.
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